Wellington Management Group LLP Acquires 160,814 Shares of Integra LifeSciences Holdings Corporation $IART

Wellington Management Group LLP raised its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 12.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,461,104 shares of the life sciences company’s stock after purchasing an additional 160,814 shares during the quarter. Wellington Management Group LLP’s holdings in Integra LifeSciences were worth $26,241,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Rubric Capital Management LP lifted its stake in shares of Integra LifeSciences by 1.3% during the 4th quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after buying an additional 100,000 shares during the last quarter. Paradigm Capital Management Inc. NY grew its stake in Integra LifeSciences by 50.6% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock valued at $37,800,000 after buying an additional 1,347,700 shares during the last quarter. Invesco Ltd. grew its stake in Integra LifeSciences by 0.9% in the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after buying an additional 31,931 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Integra LifeSciences by 9.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after acquiring an additional 267,134 shares during the period. Finally, State Street Corp lifted its position in Integra LifeSciences by 0.8% during the fourth quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after acquiring an additional 21,717 shares during the last quarter. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $16.72 on Friday. The business has a fifty day moving average price of $17.80 and a two-hundred day moving average price of $14.45. The stock has a market capitalization of $1.30 billion, a PE ratio of -185.76, a P/E/G ratio of 0.86 and a beta of 1.21. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. Integra LifeSciences Holdings Corporation has a fifty-two week low of $8.70 and a fifty-two week high of $20.49.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The company had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IART has been the subject of a number of research analyst reports. BMO Capital Markets started coverage on Integra LifeSciences in a report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price objective for the company. Citigroup reissued a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a report on Thursday, June 18th. Truist Financial increased their price objective on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Finally, Wall Street Zen downgraded Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $18.86.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.